Mccannmogensen9602

Liver and gastrointestinal diseases are frequent in women with Turner syndrome. However, their association with bleeding disorders, anaemia and the impact of hormone replacement therapy is unknown.

To investigate the risk of liver and gastrointestinal diseases, haemorrhage and anaemia in women with Turner syndrome compared with the female background population, and the long-term impact of hormone replacement therapy on these conditions.

One thousand one hundred and fifty-six women with Turner syndrome diagnosed during 1960-2014 were identified using the Danish Cytogenetic Central Registry and linked with personal-level data from the National Patient Registry and the Medication Statistics Registry. Statistics Denmark randomly identified 115577 age-matched female controls. Negative binomial regression was used to analyse hospital discharge diagnoses. Medical prescriptions, mortality and the effect of hormone replacement therapy were estimated using stratified Cox regression.

Liver disease increased 13-fer disease was higher than previously reported. The occurrence of gastrointestinal haemorrhage and anaemia was increased in Turner syndrome. There was no effect of hormone replacement therapy on gastrointestinal risk but a trend towards a beneficial impact on liver diseases was detected.

The risk of being diagnosed with liver disease was higher than previously reported. The occurrence of gastrointestinal haemorrhage and anaemia was increased in Turner syndrome. read more There was no effect of hormone replacement therapy on gastrointestinal risk but a trend towards a beneficial impact on liver diseases was detected.

To quantify the use of anterior torso skin surface position measurement as a breathing surrogate.

Fourteen patients were scanned 25 times in alternating directions using a free-breathing low-mA fast helical CT protocol. Simultaneously, an abdominal pneumatic bellows was used as a real-time breathing surrogate. The imaged diaphragm dome position was used as a gold standard surrogate, characterized by localizing the most superior points of the diaphragm dome in each lung. These positions were correlated against the bellows signal acquired at the corresponding scan times. The bellows system has been shown to have a slow linear drift, and the bellows-to-CT synchronization process had a small uncertainty, so the drift and time offset were determined by maximizing the correlation coefficient between the craniocaudal diaphragm position and the drift-corrected bellows signal. The corresponding fit was used to model the real-time diaphragm position. To estimate the effectiveness of skin surface positions as surrogound to be an accurate surrogate, but the accuracy varied across the surface sufficiently that care would need to be taken to use the surface as an accurate and reliable surrogate. Future studies will use surface imaging to determine surface patch algorithms that utilize the entire chest as well as thoracic and abdominal breathing relationships.

The thoracic patient surface was found to be an accurate surrogate, but the accuracy varied across the surface sufficiently that care would need to be taken to use the surface as an accurate and reliable surrogate. Future studies will use surface imaging to determine surface patch algorithms that utilize the entire chest as well as thoracic and abdominal breathing relationships.

What is the central question of this study? What are the mechanisms by which equine sweat glands transport sodium, potassium and water into sweat? What is the main finding and its importance? The flux of sodium into sweat does not have an active transport component, the flux of potassium into sweat is partially dependent on an active transport mechanism, and there is no evidence for paracellular transport.

In two series of experiments, this study used radioactive sodium (Na

) and potassium (K

) to trace the net flux, and calculate the unidirectional fluxes, of these ions from extracellular fluid into sweat of horses during exercise and recovery. The effect of an oral electrolyte supplement (PNW) on the sweating responses and ion fluxes was also examined. Compared to 8litres of water (controls), provision of 8litres of PNW resulted in significantly increased sweating duration (P<0.001). Two hours before exercise,

Tc-labelled diethylene-triamine-pentaacetate (DTPA) was administered i.v. to determiespect to the current understanding of sweat gland epithelial cell ion transport mechanisms at both the basal and the apical membranes. It appears likely that the majority of ions appearing in sweat pass through sweat gland epithelial cells by transcellular mechanisms that include ion transporting pathways as well as apical vesicular exocytosis.

To determine the prevalence of nocturia and associated risk factors in the Colombian population aged ≥18 years old.

This is a cross-sectional population-based study conducted in 1060 participants in Colombia. Nocturia was assessed with the Spanish version of the ICIQ-OAB, using the ICS terminology. Descriptive statistics were used to evaluate nocturia prevalence. Logistic regression analysis was carried out to determine the association of nocturia with predefined variables.

The prevalence of nocturia was 55.9% and it was more common in women than men (53.96% vs. 46.04%; p = .004). At least three episodes of nocturia were observed in 20.37% of the participants who had a severe alteration in their quality of life (p < .01). The bivariate model showed an association between nocturia and obesity (odds ratio [OR], 1.69; 90% confidence interval [CI] 1.22-2.34), diabetes mellitus (OR, 2.99; 90% CI 1.86-4.83), high blood pressure (OR, 2.04; 90% CI 1.52-2.72), cardiovascular disease (OR, 1.75; 90% CI 1.08 - 2of life. We consider important to inquire about history of childhood enuresis to define the risk of presenting nocturia in adulthood. Nocturia was associated with multiple comorbidities. Obesity and erectile dysfunction play an important role as modifiable risk factor.

To study the efficacy of phosphodiesterase-5 inhibitor tadalafil in attenuating adverse events after low-dose-rate brachytherapy for prostate cancer.

This was a randomized open-label trial, conducted at two institutions. Prostate cancer patients undergoing low-dose-rate brachytherapy were randomly assigned to receive tadalafil (study group) or tamsulosin (control group). The primary endpoint was International Prostate Symptom Score for subjective evaluation of lower urinary tract symptoms. Uroflowmetry, postvoid residual urine volume, and Sexual Health Inventory for Men score were the secondary endpoints. Each clinical variable was evaluated during a follow-up period of 1year after low-dose-rate brachytherapy.

A total of 107 patients were enrolled in this study, with a final total of 96 patients analyzed. The mean total International Prostate Symptom Score changes at 1, 3, 6, 9, and 12months after low-dose-rate brachytherapy were +7.4, +7.1, +4.7, +1.5, and +0.8, respectively, in the tamsulosin group, and +8.